

# NASEM Committee on the Assessment of NIH Research on Women's Health

#### Janine Austin Clayton, M.D., FARVO


NIH Associate Director for Research on Women's Health Director, Office of Research on Women's Health National Institutes of Health

**December 14, 2023** 

# **Outline**

- I. Statement of Task
- II. Policy Timeline
- III. Sex as a Biological Variable
- IV. Women's Health
- V. Budget and Funding
- **VI. White House Initiative**







# Statement of Task (1)

- The National Academies of Sciences, Engineering, and Medicine (NASEM) will convene a consensus committee with specific scientific, ethical, regulatory, and policy expertise to develop a framework for addressing the persistent gaps that remain in the knowledge of women's health across all NIH Institute and Centers (ICs).
- Specifically, the study should be designed to analyze the proportion of research that the NIH funds on conditions that are female-specific and/or more common amongst women or that differently impact women (e.g., different pathophysiology or course of disease), establish how these conditions are defined and ensure that it captures conditions across the lifespan, evaluates sex differences and racial and ethnic health disparities.
- The committee should define women's health for the purpose of the report, taking into account today's social and cultural climate.
- Ultimately, the study should determine the appropriate level of funding that is needed to address gaps in women's health research at NIH.





# Statement of Task (2)

- The NASEM consensus committee, as a first step, will conduct an analysis and develop a matrix of identified NIH research on conditions that are femalespecific, more common amongst women or that differently impact women, investigating sex differences, and centered on the unique health needs of women.
- The NASEM consensus committee will make recommendations for the following:
  - Research priorities for NIH-supported research on women's health,
  - NIH training and education efforts to build, support, and maintain a robust women's health research workforce,
  - NIH structure (extra- and intra-mural), systems, and review processes to optimize women's health research,
  - NIH-wide workforce to effectively solicit, review, and support women's health research,
  - Allocation of funding needed to address gaps in women's health research at NIH.
- The committee will identify metrics to ensure that research is tracked to meet the continuing health needs of women.




## **ORWH Mission**



Enhance and expand women's health research

groups in clinical research

Include women and minority



## **NIH Vision**



Sex and gender integrated into biomedical research



Every woman receives evidence-based care



Promote career advancement for women in biomedical careers



Women in science careers reach their full potential



#### **Timeline of NIH Inclusion Policies**

1986 1994 1998 2017 2019 2022

NIH encourages inclusion of women

NIH requires inclusion of women and members of racial and ethnic minority groups

NIH requires inclusion of children

New phase 3 reporting requirements

NIH requires inclusion of individuals of all ages

NIH clarifies phase 3 project outcomes requirements






# NIH Supported Research Plays a Critical Role in the Health of Women



Women's Health Initiative





Study of Women's Health
Across the Nation



EVATAR™ Modeling the Female Reproductive
Tract in 3-D







NIH-supported basic research on the immune system in the 1990s led to the development of Janus kinase (JAK) inhibitors—a class of drugs routinely used to treat a wide range of autoimmune disorders. To date, eight JAK inhibitors have been FDA-approved for treatment of a range of disorders.

Image credit: Illustration by Emw - Own work, based on PyMOL rendering of PDB Tyvj. CC BYsa 2.0

sh.wikipedia.org/wiki/Janus\_kinaza\_3#/media/ Datoteka:Protein\_JAK3\_PDB\_1yvj.png


NIH-supported basic science led to JAK inhibitor development








## Does Sex Matter? A 2001 NASEM Report



"A common, recurring message emerged ...
This message is that sex—that is, being male or female—is an important basic human variable that should be considered when designing and analyzing the results of studies in all areas and at all levels of biomedical and health related research."




## **Assumptions about Sex in Biomedical Research**




- Fundamental biology assumed to include shared molecular biochemical and physiologic characteristics
- These assumptions have led to evidence gaps

# Over-Reliance on Male Models & Lack of Analysis by Sex

# Animal Studies in Neuroscience, 2010 & 2014, by Journal



Primary Cell Culture Studies in 2016, by ASM Journal






# NIH Policy on Sex as a Biological Variable (SABV)

"NIH expects that [SABV] will be factored into research designs, analyses, and reporting in vertebrate animal and human studies.

the scientific literature, preliminary data, or other relevant considerations must be provided for applications proposing to study only one sex."



## Does Sex Matter? A 2001 NASEM Report



"A common, recurring message emerged ... This message is that sex—that is, being male or female—is an important basic human variable that should be considered when designing and analyzing the results of studies in all areas and at all levels of biomedical and health related research.

Differences in health and illness between individuals are influenced not only by individuals' genetic and physiological constitutions but also by environmental and experiential factors, all of which interact."





Interaction

# Extended ORWH Multidimensional Framework that Represents the Intersection of Factors Affecting the Health of Women

#### HEALTH OF WOMEN ACROSS THE LIFE SPAN

Women in Context and Society – **External** Factors
Such as **gender**, **generation**, **race/ethnicity** influences at individual, interpersonal, community, & societal levels

Pre-Pregnancy

In Utero

Childhood Adolescence

Adulthood


Biological Perspective – **Internal** Factors such as **sex & age** influences at genetic, molecular, cellular, & physiological levels



nteraction

#### Sex and Gender Influence Health


Dimensions of Sex (Biological Variable) & Gender (Social and Cultural Variable)



#### **Dimensions of Intersectionality\***

The culmination of a person's multiple domains of identity combined with their lived experience that together influence health status and disease risk (i.e., race, ethnicity, socioeconomic status, generation, caste, sexual orientation).


#### **Differences in Health for Women**



Data source: UN, World Population Prospects (2022)

OurWorldInData.org/life-expectancy | CC BY

Percent of women ages 18-64 who had two or more chronic conditions<sup>^</sup>



Notes: A Having a chronic disease defined as ever being told by a doctor as having two or more of the following: joint pain or arthritis; asthma or chronic lung disease; diabetes; heart disease, including heart attack; or high blood pressure. Statistically significant difference compared to the United States (p<.05).

Data: The Commonwealth Fund International Health Policy Survey, 2016.






<sup>1.</sup> Period life expectancy: Period life expectancy is a metric that summarizes ceath rates across all age groups in one particular year. For a given year, it represents the average lifescan for a hypothetical group of people. If they experienced the same age-specific death rates throughout their whole lives as the age-specific death rates seen in that particular year. Learn more in our article: "Life expectancy" - What does this actually mean?

# **Defining Women's Health**

| <b>Condition Type</b>                     | Examples   |  |
|---|--|--|
| Female specific                           | <ul><li> Endometriosis</li><li> Cervical Cancer</li><li> Menopause</li></ul>       |  |
| Disproportionately impact women           | <ul><li>Autoimmune Disease</li><li>Mental Health</li><li>Pain Conditions</li></ul> |  |
| Present and progress differently in women | <ul><li>Heart Disease</li><li>Stroke</li><li>Metabolic Disorders</li></ul>         |  |



# What is ORWH's relation to the rest of NIH?


ORWH co-funds & complements ICO research

**NIH-wide WHR Biennial Report** 





# Collaboration is Key to Women's Health Research at NIH



0

## >>> ORWH Advances Study of Sex & Gender and the **Health of Women through Collaborations across NIH**

#### **BIRCWH**

Building Interdisciplinary Research Careers in Women's Health

#### 8 ICOs

**Mentored** Career Development



#### **SCORE**

Specialized Centers of Research Excellence on Sex Differences

#### 6 ICOs

Disease-**Agnostic** Research Centers



RFA-OD-22-014


#### Administrative Supplements

Sex and Gender 22 ICOs

Understudied. Underrepresented, & Underreported (U3)

#### 16 ICOs

**Funding Program to Expand Sex & Gender Data** 



#### **R01**

Intersection of sex & gender influences on health & disease

#### 11 ICOs

Sex & Gender **Influences on** Health & Disease



RFA-OD-22-028

#### R21 & R01

Understanding **Chronic Conditions** Understudied Among Women

#### 6 ICOs

A 2021 Women's **Health Conference** Report




RFA-OD-23-103 RFA-OD-23-014

# NOSI: Administrative Supplements for Research on Women's Health in the IDeA States – 2023 Update

| NOTICE            | NOT-GM-22-005   |
|-------------------|---|
| DUE DATE          | October 17, 2022; October 17, 2023; and October 17, 2024  |
| GOAL              | To expand research and research capacity in the IDeA states to address important issues of women's health across the lifespan. Research on maternal and infant morbidity and mortality is of particular interest.                   |
| ISSUED BY 16 ICOs | NIGMS with ORWH, NEI, NHLBI, NIA, NIAID, NIBIB, NICHD, NIDCR, NIDA, NIEHS, NINR, NCCIH, NCI, ODP, SGMRO   |
| BUDGET            | Up to \$200,000 for 1 year in direct costs.   |
| CONTACTS          | Crina Frincu (NIGMS)— Inquiries related to IDeA program and policy requirements  Regine Douthard (ORWH) — inquiries related to scientific content of the applications  POs from each ICO are listed to answer IC-specific questions |
| FUNDING           | \$16.4 million awarded: 60 grants in 20 IDeA states & Puerto Rico since 2020  |



# ORWH partners with NIGMS and ICs on Women's Health Research in IDeA States





# NIH funded randomized controlled trials reporting outcomes by sex (and race and ethnicity) increased significantly

Table 2. Inclusion and Analysis by Sex in National Institutes of Health-Funded Clinical Trials Published in 2004, 2009, 2015, and 2021

|  | 2004         | 2009         | 2015         | 2021         |                           |
|--|--------------|--------------|--------------|--------------|---------------------------|
| Enrollment by sex Median % of women enrolled (interquartile range)                                   | 43% (25–61%) | 38% (28–54%) | 46% (34–56%) | 44% (24–56%) |                           |
|  | n (%)        | n (%)        | n (%)        | n (%)        | Fisher's exact<br>p-value |
| Analysis and reporting by sex<br>Analysis by sex provided or<br>sex included in statistical analysis | 6 (13.0)     | 14 (25.0)    | 28 (26.2)    | 34 (43.0)    | < 0.01                    |
| Did not analyze by sex, but<br>provided explanation  | 9 (19.6)     | 6 (10.7)     | 2 (1.9)      | 5 (6.3)      |                           |
| Did not include sex in analysis<br>or provide an explanation   | 31 (67.4)    | 36 (64.3)    | 77 (72.0)    | 40 (50.6)    |                           |
| Total  | 46 (100.0)   | 56 (100.0)   | 107 (100.0)  | 79 (100.0)   |                           |


Analysis and reporting by sex, race, and ethnicity significantly increased despite no corresponding increase in enrollment.

Among studies enrolling male and female participants.

Koch, A. R., Craemer, K. A., Garland, C. E., Fox, W. B., Jones, C. T., Qualls, A. C., Sterr, J. C., & Geller, S. E. (2023). Federally Funded Randomized Controlled Trials Increase Analysis and Reporting of Study Outcomes by Sex, Race, and Ethnicity. Journal of women's health (2002), 10.1089/jwh.2023.0307. Advance online publication. https://doi.org/10.1089/jwh.2023.0307



# NIH-Wide Research Investments in Women's Health (\$4.6 Billion)









#### **ORWH Budget History & FY2022 Extramural Grant Award Profile**

#### **ORWH Budget History**



Fiscal Year

Note: Award investments do not adjust for inflation.



# ORWH FY2022 Extramural Grant Awards by Program (as % of Extramural Budget)

Source: NIH IMPAC II FY2022 frozen data.

Note: ORWH total investments = \$43,222,779. Funding portfolio excludes R&D contracts, IAA, and Loan Repayment awards.





#### **ORWH Budget History & FY2022 Extramural Grant Award Profile**

\$76,480,000 for ORWH \$10,000,000 for OADR-ORWH \$5,000,000 for BIRCWH \$2,000,000 for NASEM study


Note: FY23 Appropriations are not separated by category

# Women's Health Research Spending By Category





# FY22 NIH Funding for Women's Health – Training (T F K awards) (\$232 million)




## **FY21** House and Senate "Significant Items"

The ORWH held the **Advancing NIH Research on the Health of Women: A 2021 Conference** on October 20, 2021, as part of the ACRWH Meeting.

- Evaluate research and identify priorities to advance the study of women's health
- Coordinated with the CCRWH


House: https://www.congress.gov/116/crpt/hrpt450/CRPT-116hrpt450.pdf (page 149), Senate: https://www.appropriations.senate.gov/imo/media/doc/LHHSRept.pdf (page 123)

# Rising Rates of Maternal Morbidity and Mortality




2015, Source: The Lancet. Credit: Rob Weychert/ProPublica

# Rising Rates of Chronic Debilitating Conditions in Women



King, DE, etal. JABFM 2018, 31 (4) 503-513.

# Stagnant Survival Rates among Cervical Cancer Patients




https://seer.cancer.gov/statfacts/html/cervix.html




## Crosscutting Themes Identified: Where Research is "Urgently Needed"

- Implementing best practices evidence-based and more holistic, patient-centered care
- 2. Addressing care inequities especially among populations with overlapping identities
- 3. Intentional research two components:
  - Historic overreliance on male clinical research participants left significant gaps regarding female-specific disorders and diseases more common in women
  - Despite Sex As a Biological Variable (SABV) policy, gaps remain in basic and translational understanding of sex differences











THE WHITE HOUSE WASHINGTON

**Section 5: Recommendations to the President.** Within 45 days of the date of this memorandum, the members of the Initiative or their designees shall provide recommendations to the President, through the Chair, on concrete actions that agencies and offices can take to advance women's health research.

